Podcasts about bioscience

We're bringing back the episode where we dig into decades-old crop-content studies to quantify exactly how much of a turkey's diet is acorns, and what the trends in declining oak forests mean for the future of wild turkeys.   Resources: Alexander et al. (2021). Mesophication of oak landscapes: Evidence, knowledge gaps, and future research. BioScience, 71(5), 531-542. Burk et al. (1990). Wild turkey use of streamside management zones in loblolly pine plantations. In Proceedings of the National Wild Turkey Symposium (Vol. 6, pp. 84-89). Byrne, M. E. (2013). Nesting ecology of wild turkeys in a bottomland hardwood forest. The American Midland Naturalist, 170(1), 95-110. Davis et al. (2018). Landscape-abundance relationships of male Eastern Wild Turkeys Meleagris gallopavo silvestris in Mississippi, USA. Acta ornithologica, 52(2), 127-139. Marable et al. (2023). Seasonal Resource Selection and Use of Hardwood Regeneration by Translocated Wild Turkeys in the Mississippi Alluvial Valley. Diversity, 15(9), 1007. McShea et al. (2007). Forestry matters: decline of oaks will impact wildlife in hardwood forests. The Journal of Wildlife Management, 71(5), 1717-1728. Nelson et al. (2022). Fine‐scale resource selection and behavioral tradeoffs of eastern wild turkey broods. The Journal of Wildlife Management, 86(5), e22222. Nelson et al. (2023). Age‐based shifts in habitat selection of wild turkey broods. The Journal of Wildlife Management, e22494. Norman & Steffen (2003). Effects of recruitment, oak mast, and fall-season format on wild turkey harvest rates in Virginia. Wildlife Society Bulletin, 553-559. Norman et al. (2022). Hunting and environmental influences on survival of male wild turkeys in Virginia and West Virginia. Wildlife Society Bulletin, 46(2), e1284. Schemnitz, S. D. (1956). Wild turkey food habits in Florida. The Journal of Wildlife Management, 20(2), 132-137. Thogmartin, W. E. (2001). Home-range size and habitat selection of female wild turkeys (Meleagris gallopavo) in Arkansas. The American Midland Naturalist, 145(2), 247-260.   Get your tickets to our 2nd Annual UF Game Lab Banquet here: https://tinyurl.com/UFGameLabBanquet   Can't attend the banquet but still want to bid on our live auction items? Email c.nowak@ufl.edu or send a DM to our UF Game Lab Instagram or Facebook.    Can't attend the banquet but still want to support us? Please donate here: http://UFgive.to/UFGameLab. Thank you in advance for your support!   We've launched our second online wild turkey course  ! Enroll in  Wild Turkey Manager: Biology, History & Habitat to learn about the principal biology, mating, behavior, food selection, human dimensions, hunter interactions, and historical context of wild turkeys. This course is accredited by the Society of American Foresters as a Category 2 course worth 7 Continuing Forestry Education credits. Participants can also earn up to 5 CEUs in Category I of The Wildlife Society's Certified Wildlife Biologist Program. Enroll now: https://tinyurl.com/WildTurkeyManagerBio   Be sure to check out our first comprehensive online wild turkey course featuring experts across multiple institutions that specialize in habitat management and population management for wild turkeys. Earn up to 20.5 CFE hours! Enroll Now!    Dr. Marcus Lashley @DrDisturbance, Publications Dr. Will Gulsby @dr_will_gulsby, Publications Turkeys for Tomorrow @turkeysfortomorrow  UF Game Lab @ufgamelab, YouTube   Want to help wild turkey conservation? Please take our quick survey to take part in our research!   Do you have a topic you'd like us to cover? Leave us a review or send us an email at wildturkeyscience@gmail.com!   Watch these podcasts on YouTube   Please help us by taking our (quick) listener survey - Thank you!    Check out the DrDisturbance YouTube channel! DrDisturbance YouTube   Want to help support the podcast? Our friends at Grounded Brand have an option to donate directly to Wild Turkey Science at checkout. Thank you in advance for your support!   Leave a podcast rating for a chance to win free gear!   This podcast is made possible by Turkeys for Tomorrow, a grassroots organization dedicated to the wild turkey. To learn more about TFT, go to turkeysfortomorrow.org.    Music by Artlist.io Produced & edited by Charlotte Nowak

We're bringing back the episode where we dig into decades-old crop-content studies to quantify exactly how much of a turkey's diet is acorns, and what the trends in declining oak forests mean for the future of wild turkeys.   Resources: Alexander et al. (2021). Mesophication of oak landscapes: Evidence, knowledge gaps, and future research. BioScience, 71(5), 531-542. Burk et al. (1990). Wild turkey use of streamside management zones in loblolly pine plantations. In Proceedings of the National Wild Turkey Symposium (Vol. 6, pp. 84-89). Byrne, M. E. (2013). Nesting ecology of wild turkeys in a bottomland hardwood forest. The American Midland Naturalist, 170(1), 95-110. Davis et al. (2018). Landscape-abundance relationships of male Eastern Wild Turkeys Meleagris gallopavo silvestris in Mississippi, USA. Acta ornithologica, 52(2), 127-139. Marable et al. (2023). Seasonal Resource Selection and Use of Hardwood Regeneration by Translocated Wild Turkeys in the Mississippi Alluvial Valley. Diversity, 15(9), 1007. McShea et al. (2007). Forestry matters: decline of oaks will impact wildlife in hardwood forests. The Journal of Wildlife Management, 71(5), 1717-1728. Nelson et al. (2022). Fine‐scale resource selection and behavioral tradeoffs of eastern wild turkey broods. The Journal of Wildlife Management, 86(5), e22222. Nelson et al. (2023). Age‐based shifts in habitat selection of wild turkey broods. The Journal of Wildlife Management, e22494. Norman & Steffen (2003). Effects of recruitment, oak mast, and fall-season format on wild turkey harvest rates in Virginia. Wildlife Society Bulletin, 553-559. Norman et al. (2022). Hunting and environmental influences on survival of male wild turkeys in Virginia and West Virginia. Wildlife Society Bulletin, 46(2), e1284. Schemnitz, S. D. (1956). Wild turkey food habits in Florida. The Journal of Wildlife Management, 20(2), 132-137. Thogmartin, W. E. (2001). Home-range size and habitat selection of female wild turkeys (Meleagris gallopavo) in Arkansas. The American Midland Naturalist, 145(2), 247-260.   Get your tickets to our 2nd Annual UF Game Lab Banquet here: https://tinyurl.com/UFGameLabBanquet   Can't attend the banquet but still want to bid on our live auction items? Email c.nowak@ufl.edu or send a DM to our UF Game Lab Instagram or Facebook.    Can't attend the banquet but still want to support us? Please donate here: http://UFgive.to/UFGameLab. Thank you in advance for your support!   We've launched our second online wild turkey course  ! Enroll in  Wild Turkey Manager: Biology, History & Habitat to learn about the principal biology, mating, behavior, food selection, human dimensions, hunter interactions, and historical context of wild turkeys. This course is accredited by the Society of American Foresters as a Category 2 course worth 7 Continuing Forestry Education credits. Participants can also earn up to 5 CEUs in Category I of The Wildlife Society's Certified Wildlife Biologist Program. Enroll now: https://tinyurl.com/WildTurkeyManagerBio   Be sure to check out our first comprehensive online wild turkey course featuring experts across multiple institutions that specialize in habitat management and population management for wild turkeys. Earn up to 20.5 CFE hours! Enroll Now!    Dr. Marcus Lashley @DrDisturbance, Publications Dr. Will Gulsby @dr_will_gulsby, Publications Turkeys for Tomorrow @turkeysfortomorrow  UF Game Lab @ufgamelab, YouTube   Want to help wild turkey conservation? Please take our quick survey to take part in our research!   Do you have a topic you'd like us to cover? Leave us a review or send us an email at wildturkeyscience@gmail.com!   Watch these podcasts on YouTube   Please help us by taking our (quick) listener survey - Thank you!    Check out the DrDisturbance YouTube channel! DrDisturbance YouTube   Want to help support the podcast? Our friends at Grounded Brand have an option to donate directly to Wild Turkey Science at checkout. Thank you in advance for your support!   Leave a podcast rating for a chance to win free gear!   This podcast is made possible by Turkeys for Tomorrow, a grassroots organization dedicated to the wild turkey. To learn more about TFT, go to turkeysfortomorrow.org.    Music by Artlist.io Produced & edited by Charlotte Nowak

Send us Fan MailMost of us think of medicine as something we take every day - a statin, a blood pressure pill, or perhaps a monthly injection. But what if those lifelong treatments eventually become obsolete? What if one carefully targeted gene edit could dramatically reduce your risk of heart disease for decades? Dr. Trevor Martin, Ph.D. is the Co-Founder and Chief Executive Officer of Mammoth Biosciences ( https://mammoth.bio/ ), a pioneering biotechnology company developing next-generation CRISPR genome editing technologies for potentially curative medicines. He co-founded the company in 2017 alongside Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna and an interdisciplinary team of leading scientists with the goal of building more precise, versatile, and clinically practical gene editing systems.Dr. Martin earned his undergraduate degree in Molecular Biology with honors from Princeton University before completing a Ph.D. in Genetics and Statistics at Stanford University, where his research focused on quantitative genetics, genomics, and computational biology. His scientific background in statistics and genetics has shaped Mammoth's unique approach to developing smaller CRISPR enzymes capable of reaching tissues and diseases that have been difficult to target with first-generation technologies.Under Dr. Martin's leadership, Mammoth has grown into one of the world's leading CRISPR companies, raising more than $465 million, achieving a valuation exceeding $1 billion, and establishing strategic collaborations with companies including Vertex Pharmaceuticals, Bayer, and Regeneron Pharmaceuticals.Today, Mammoth is advancing a pipeline of in vivo gene editing therapies, including programs targeting cardiovascular disease through permanent editing of the APOC3 gene - a potential one-time treatment approach aimed at dramatically reducing triglycerides and long-term cardiovascular risk. Beyond therapeutics, the company's CRISPR platform also extends into diagnostics and genome engineering technologies that may reshape medicine over the coming decades.Dr. Martin has been recognized as an EY Entrepreneur of the Year®, Forbes 30 Under 30, and Fortune 40 Under 40 honoree for his contributions to biotechnology and scientific entrepreneurship.#CRISPR #GeneEditing #TrevorMartin #MammothBiosciences #JenniferDoudna #Biotechnology #GenomeEditing #HeartDisease #Longevity #FutureOfMedicine #PrecisionMedicine #Genetics #DNA #HealthInnovation #MedicalBreakthrough #CardiovascularDisease #SciencePodcast #Biotech #Innovation #ProgressPotentialPossibilitiesSupport the show

GreenLight Biosciences' Jonathan Adamson says they've shown that RNA can be a viable solution to control the pests that potato growers deal with regularly

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

Dr. Ryan Beal, Founder and CEO of Dyve Biosciences, has developed a transdermal delivery approach that uses the skin to deliver agents into circulation, where they selectively neutralize the acidic tumor microenvironment. By correcting acidity, the immune system is reactivated to better recognize and attack cancer cells, as acidity serves as a natural immune checkpoint that allows tumors to evade immune surveillance. Unlike previous oral delivery approaches that cause gastrointestinal side effects, this non-invasive lotion-based technology delivers the same pharmaceutical safety and efficacy. Ryan explains, "What led me there is that tumor acidity has driven cancer biology for decades. The science has settled. What was missing was a way to actually fix it in patients and do it safely, broadly, and at scale. And that's what Dyve built. In 2026, the goal is to bring it into humans with trials at Moffitt Cancer Center."   "The core at Dyve was developing the delivery system. It could bring molecules through the skin. And one of the approaches that we got quite excited about early on was delivering buffering agents through the skin. The natural application was in oncology and going after the acidity of the tumor microenvironment."   "So it's a topical. In many ways it will look and feel like a lotion, and it's applied to the skin but delivered systemically. So we're essentially turning the skin into a delivery portal for these drugs. And that's important, especially important in the case of tumor acidity.  Because we and others have shown that while in animals you can deliver these therapies orally, it's a big delivery challenge for humans to take these agents orally. So you needed another way to circumvent those problems, and the skin gave us a really convenient path to do that." #DyveBiosciences #MoffittCancerCenter #CancerResearch #Oncology #CancerTreatment #Immunotherapy #PrecisionMedicine #DrugDevelopment #ClinicalTrials #TumorMicroenvironment #TransdermalDelivery #Biotechnology #OncologyInnovation #TransdermalTherapy #DrugDelivery #CancerCare #HealthcareInnovation DyveBio.com Download the transcript here

Dr. Ryan Beal, Founder and CEO of Dyve Biosciences, has developed a transdermal delivery approach that uses the skin to deliver agents into circulation, where they selectively neutralize the acidic tumor microenvironment. By correcting acidity, the immune system is reactivated to better recognize and attack cancer cells, as acidity serves as a natural immune checkpoint that allows tumors to evade immune surveillance. Unlike previous oral delivery approaches that cause gastrointestinal side effects, this non-invasive lotion-based technology delivers the same pharmaceutical safety and efficacy. Ryan explains, "What led me there is that tumor acidity has driven cancer biology for decades. The science has settled. What was missing was a way to actually fix it in patients and do it safely, broadly, and at scale. And that's what Dyve built. In 2026, the goal is to bring it into humans with trials at Moffitt Cancer Center."   "The core at Dyve was developing the delivery system. It could bring molecules through the skin. And one of the approaches that we got quite excited about early on was delivering buffering agents through the skin. The natural application was in oncology and going after the acidity of the tumor microenvironment."   "So it's a topical. In many ways it will look and feel like a lotion, and it's applied to the skin but delivered systemically. So we're essentially turning the skin into a delivery portal for these drugs. And that's important, especially important in the case of tumor acidity.  Because we and others have shown that while in animals you can deliver these therapies orally, it's a big delivery challenge for humans to take these agents orally. So you needed another way to circumvent those problems, and the skin gave us a really convenient path to do that." #DyveBiosciences #MoffittCancerCenter #CancerResearch #Oncology #CancerTreatment #Immunotherapy #PrecisionMedicine #DrugDevelopment #ClinicalTrials #TumorMicroenvironment #TransdermalDelivery #Biotechnology #OncologyInnovation #TransdermalTherapy #DrugDelivery #CancerCare #HealthcareInnovation DyveBio.com Listen to the podcast here

For this episode, we're joined by Prosanta Chakrabarty, Director of Louisiana State University's Museum of Natural Science, where he is also the Fish Curator and a professor. Also joining us is Bruno Soares, Scientist and Adjunct Professor at the University of Regina in Canada. Dr. Soares holds a Collaborator-Professor appointment at the Federal University of Rio De Janeiro, in Brazil. They were here to talk about their recent publication in BioScience on the concept of type localities, and how their use can help make taxonomic research more equitable and efficient. 

Water has long been at the center of debates about homeopathy, and Marcus sits down with homeopath and hydration educator Yasmine Miles to explore why. Yasmine shares how growing up with homeopathy, followed by her own struggles with PTSD, panic attacks, and digestive issues while studying biomedical science, ultimately led her to pursue homeopathy after experiencing meaningful improvements in her health. Their conversation traces her journey through skepticism, criticism from the biomedical community, and a growing interest in the science of water. Together, they discuss topics including water memory, coherent water domains, and research exploring how water may interact with biological systems and homeopathic remedies. Episode Highlights: 03:39 - Why So Many Find Homeopathy Last 07:00 - When Everything Suddenly Made Sense 08:23 - Trapped in the System 09:19 - The Healing Hidden in Plain Sight 12:32 - Homeopathy Finds You 16:17 - Facing Skeptics Head On 19:25 - Flexner Report Backstory 22:24 - Dr. Pollack's work on the fourth phase of water 24:08 - Infrared Boosts EZ Water 27:09 - Water Memory Proof 29:39 - Succussion Mechanism 32:20 - Understanding Coherent Water Domains 37:01 - The Overlooked Role of Water 39:11 - Key Not Cure About my Guests: Yasmine Miles LCHE, BSc (Hons) is a Homeopath, Flower Essence Practitioner, and Hydration Educator. After healing from PTSD with homeopathy during her Biosciences degree, she pivoted into homeopathic training with CHE in 2018, where her fascination with the nature of water and its relation to homeopathy was sparked.  Her work now bridges homeopathy, flower essences, and quantum biology, exploring living water as a coherent, intelligent medium for vibrational healing.  Yasmine practises internationally online and leads in-person workshops on homeopathy & hydration. She is currently training with Dr Catherine Clinton in Quantum Biological Health and collaborates extensively with CHE to elevate the profession. Find out more about Yasmine Instagram: https://www.instagram.com/hydratedhomeopath/ https://wakewaterco.com/ If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode. Learn more about CHE Australia and its homeopathy training programs: https://chehomeopathy.com.au/ Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/ Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom                

Friday on a Thursday! We're joined by Miles Harrison, CEO of Conexeu Sciences (Nasdaq: CNXU), to discuss the intersection of AI and bioscience + how GLP-1s are carving out a new market for them. Click here to learn more!---

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

⚽️

Two Ebola drugs are due to be trialled in the Democratic Republic of Congo (DRC) as cases of the disease continue to rise in the country. BBC health and science correspondent James Gallagher joins Claudia Hammond to discuss the new clinical trial, and to update on the latest from the outbreak in the DRC and Uganda.Claudia also visits The Royal Society's annual Summer Science Exhibition in London to explore a range of new health research on display.We hear about how salt water is being used to try to make lateral flow tests more sensitive and targeted, with Guido Bolognesi and Nguyen Thi Kim Thanh from University College London. They also explain the role gold nanoparticles play in current lateral flow tests, which rapidly diagnose pregnancy or Covid-19.Claudia also visits a 'microbe zoo' and speaks with Revathy Krishnamurthy from the Quadram Institute of Bioscience in Norwich, England, who explains what phages are, and how they can be harnessed to improve food safety.Finally, we meet Pat Price, visiting professor at Imperial College London, to learn about the high-energy particles that could kill cancer cells, how they could completely change treatment for patients, and how it's hoped lasers can help them accomplish it.Image Credit: Credit: Photo by DIEUDONNE DIROLE/EPA/ShutterstockPresenter: Claudia Hammond Producer: Dan Welsh and Georgia Christie

interview

For this episode, we were joined by Anna Rader Groves, Amanda Finn, and Alex Rich from the Scientist Network for Advancing Policy, or SNAP. They were here to discuss their recent special report in BioScience that describes the grassroots coalition and some of its important work in helping early-career scientists reach the general public and policymakers. Sign up for the SNAP newsletter.Learn more about Stance on Science.Volunteer with Stance on Science. More information about AIBS workshops and programs, including Congressional Visits, Communications Bootcamps, and Writing for Impact and Influence, can be found here.

What if the future of skincare wasn't about trends — but about real science and long-term skin health? On today's episode, we welcome Dr. Dhaval Bhanusali, board-certified dermatologist and co-founder of Elm Biosciences — a company combining in-office treatments with smarter at-home routines. If you're interested in understanding the science behind skincare, making better decisions for your skin, or staying ahead of where the industry is going — this one's for you. Tune in now on The Kara Goldin Show.   Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.   To learn more about Dr. Dhaval Bhanusali and Elm Biosciences:https://elmbiosciences.com/https://www.instagram.com/dhbhanusali/https://www.linkedin.com/in/dhaval-bhanusali/https://bhanusalimd.com/   Sponsored By: Fatty15 - Get an additional 15% off a 90-day subscription Starter Kit by going to Fatty15.com/KARA and using code KARA at checkout. Acorns - Head to Acorns.com/KARA or download the Acorns app to get started. LinkedIn Jobs - Head to LinkedIn.com/KaraGoldin to post your job for free. Upwork - Visit Upwork.com right now and post your job for free. Rippling - Head to Rippling.AI/KaraGoldin and get the only AI to give you full visibility across your business and take complex actions across your entire organization.   Check out our website to view this episode's show notes: https://karagoldin.com/podcast/852

O Giuvan Lenz, da empresa Greenlight Biosciences, fala de uma nova ferramenta para o controle de pragas, O RNA, que não deixa resíduos.

We add another string to our bow by learning about the fiddler crab. We discuss the arc of history bending towards crab, the MogBot 2000, bad dating advice, non-orientable wormholes, and so much more.  Works Cited: “The Design of a Beautiful Weapon” - John Christy, Smithsonian Museum of Natural History “On the Other Hand: The Myth of Fiddler Crab Claw Reversal” - Judith S. Weis, BioScience, April 2019 “Sexual selection for structure building by courting male fiddler crabs: an experimental study of behavioral mechanisms” - John H. Christy et al., Behavioral Ecology, May 2002 “Synchronous waving in fiddler crabs: a review” - Patricia Ruth Yvonne Backwell, Current Zoology, July 2018 “Robotic crabs reveal that female fiddler crabs are sensitive to changes in male display rate” - Sophie L. Mowles et al., Biology Letters, January 2018 “Not what it looks like: mate-searching behaviour, mate preferences and clutch production in wandering and territory-holding female fiddler crabs” - M. Peso et al., R. Soc Open Sci.. August 2016 “Dishonest signalling of fighting ability and multiple performance traits in the fiddler crab Uca mjoebergi” - Simon P. Lailvaux et al., Functional Ecology, March 2009 “The effects of neighbor familiarity and size on cooperative defense of fiddler crab territories” - Isobel Booksmythe et al., Behavioral ecology, November 2011 “Beyond Abiotic Decay: Fiddler Crabs Accelerate Plastic Fragmentation in Pollution Hotspots” - Jose M. Riascos et al., Global Change Biology, December 2025 Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky!   Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

We add another string to our bow by learning about the fiddler crab. We discuss the arc of history bending towards crab, the MogBot 2000, bad dating advice, non-orientable wormholes, and so much more.  Works Cited: “The Design of a Beautiful Weapon” - John Christy, Smithsonian Museum of Natural History “On the Other Hand: The Myth of Fiddler Crab Claw Reversal” - Judith S. Weis, BioScience, April 2019 “Sexual selection for structure building by courting male fiddler crabs: an experimental study of behavioral mechanisms” - John H. Christy et al., Behavioral Ecology, May 2002 “Synchronous waving in fiddler crabs: a review” - Patricia Ruth Yvonne Backwell, Current Zoology, July 2018 “Robotic crabs reveal that female fiddler crabs are sensitive to changes in male display rate” - Sophie L. Mowles et al., Biology Letters, January 2018 “Not what it looks like: mate-searching behaviour, mate preferences and clutch production in wandering and territory-holding female fiddler crabs” - M. Peso et al., R. Soc Open Sci.. August 2016 “Dishonest signalling of fighting ability and multiple performance traits in the fiddler crab Uca mjoebergi” - Simon P. Lailvaux et al., Functional Ecology, March 2009 “The effects of neighbor familiarity and size on cooperative defense of fiddler crab territories” - Isobel Booksmythe et al., Behavioral ecology, November 2011 “Beyond Abiotic Decay: Fiddler Crabs Accelerate Plastic Fragmentation in Pollution Hotspots” - Jose M. Riascos et al., Global Change Biology, December 2025 Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky!   Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

10x Genomics, Inc. v. Parse Biosciences, Inc.

Tune in as Jennifer Mondillo, a gerontology nurse practitioner, and Rob Leffler, a board-certified geriatric pharmacist, explain the inappropriate use of anticholinergic medications to treat older adults with tardive dyskinesia (TD), a drug-induced movement disorder. These experts emphasize the importance of reducing or eliminating the anticholinergic burden in patients with TD and discuss practical approaches to evaluating anticholinergic use in LTC residents with drug-induced movement disorders, de-prescribing, and treating TD appropriately with VMAT2 inhibitors. This podcast was sponsored and co-developed by Neurocrine Biosciences, Inc.” This podcast is an educational program sponsored and co-developed by Neurocrine Biosciences.Neurocrine Biosciences is a pioneering company with over 30 years of experience dedicated to discovering and developing life-changing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Learn more: https://www.neurocrine.com/Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

For decades, men had Viagra. Women were told to relax and have a glass of wine. That imbalance in pharmaceutical innovation is finally changing, but it hasn't been easy.In this episode, I talk with Sabrina Johnson, the founder and CEO of Dare Bioscience the only publicly traded pharmaceutical company focused entirely on women's healthcare. We discuss why the pharmaceutical industry has historically avoided investing in women's sexual health, the stigma and sexism that surrounds female arousal and pleasure, and what it actually takes to develop and bring products to market.Sabrina walks us through the development of Dare to Play, a topical cream for sexual arousal that's coming soon, the science behind how it works, and the extensive clinical trials required to prove safety and efficacy. We also discuss other products in development a probiotic for vaginal health and a once-a-month vaginal ring for menopause with estradiol and progesterone. This is about changing what's possible for women's health.From regulatory hurdles to cultural stigma, the barriers to innovating in women's sexual health are real. In this conversation, we explore how companies can create real world solutions that actually work for women's lives, the importance of rigorous clinical testing, and why investing in women's health matters. We dive into the science, the business side, and how you can support this work.Highlights:Only 1% of private investment in pharmaceutical development goes to companies innovating solely for women which is why there's so little funding and so many gaps.The stigma is real: one NPR station refused to air an interview because Sabrina said the word "vagina" too many times.Dare to Play increases blood flow to genital tissue for sensation and lubrication the same mechanism as Viagra, but in cream form. The major innovation was developing specialized delivery technology to get sildenafil through skin and manufacturing at pharmaceutical grade standards rather than compounding standards.Dare worked with the SEC and NASDAQ to create a direct public offering so anyone can invest with just $250, not just institutional investors.I hope this episode inspires you to think differently about women's health innovation and what's possible when we demand better. If you believe in the work DARE is doing, you can support it. You don't have to donate you can become an investor with as little as $250. All the information on how to do that will be below.Get in touch with Sabrina:WebsiteBecome an InvestorInstagramLinkedInTikTokGet in Touch with Me:WebsiteInstagramYoutubeSubstack

Most of us instinctively understand that we feel better when we spend time in nature. But our relationship to the natural world is perhaps even more powerful than we appreciate. On today's episode, host Rachel is joined by Emily Long—licensed clinical social worker, certified nature-informed therapist, and yoga teacher. Emily shares research on the therapeutic benefits of building a more mindful relationship with nature, whether that means spending time outdoors, inviting natural elements indoors, even simply viewing nature through a window. Emily also reminds us how nature is deeply embedded in the yoga tradition.  From stress reduction and improved cognitive function to increased resilience and emotional regulation, this conversation highlights the many ways reconnecting with nature can support our well-being, and how our practice could be the perfect time and place to do so. "What we care for cares for us." — Emily Long. — What You'll Learn: • How yoga already reflects our connection to nature [3:08] • Stereotypes can discourage people from developing a relationship with nature [9:19] • Research: nature and our health [12:56] • "Softly fascinating stimuli" and the nervous system [16:12] • Reaping the benefits whether we enjoy nature or not [20:40] • Nature encourages social and community connection [23:44] • Practical ways to invite nature into indoor spaces [26:35] • Taking opportunities to go outside [29:02] • Natural imagery, honoring seasonal rhythms [30:59] • Ahimsa, reciprocity, and caring for the environment [37:33] — Links Mentioned: Watch this episode on YouTube Relevant research: Soga, M., & Gaston, K. J. (2025). Health benefits of viewing nature through windows: A meta-analysis. Bioscience, 75(8), 628–636. https://doi.org/10.1093/biosci/biaf089 Stevenson, M. P., Schilhab, T., & Bentsen, P. (2018). Attention Restoration Theory II: a systematic review to clarify attention processes affected by exposure to natural environments. Journal of toxicology and environmental health. Part B, Critical reviews, 21(4), 227–268. https://doi.org/10.1080/10937404.2018.1505571 Bettmann, J. E., Speelman, E., Blumenthal, E., Couch, S., & McArthur, T. (2024). How Does Nature Exposure Affect Adults With Symptoms of Mental Illness? A Meta-Analysis. International journal of mental health nursing, 33(6), 1889–1907. https://doi.org/10.1111/inm.13400 Ulrich R. S. (1984). View through a window may influence recovery from surgery. Science (New York, N.Y.), 224(4647), 420–421. https://doi.org/10.1126/science.6143402  Connect with Emily Long: Instagram | Yoga With Emily | Emily Long LCSW — Learn More: Find the full show notes at YogaMedicine.com/podcast-168. Learn more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts or wherever you listen to podcasts. 

May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

We love to hear from our listeners. Send us a message.This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy. They cover the broader challenges facing in vivo gene editing, including delivery limitations outside the liver, balancing specificity and efficiency, mitigating off-target risks, and translating promising preclinical in vivo data into clinical success.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Headlines warned us about microplastics in our brains. A chemist says the study may have been measuring brain fat instead. In 2025, a study claiming microplastics accumulate in human brain tissue dominated our feeds. We covered it. Then Dr. Michelle Wong, a chemical scientist and science communicator, flagged a problem with the methodology. So we went to the primary literature, read the critique, and brought in one of the first scientists to publicly challenge the findings: Dr. Oliver Jones, Professor of Analytical Chemistry at RMIT University in Melbourne. In this episode, we unpack what went wrong with the measurement method, what it means for the broader microplastics conversation, and why being willing to say "I was wrong" is so vital for good science. In this episode: How pyrolysis GC-MS works and why it can confuse plastic breakdown products with brain fat Why potassium hydroxide digestion creates soap, which also mimics plastic signatures The contamination problem: body bags, centrifuge tubes, plastic storage containers, and lab air Why 7 grams of microplastic per brain is more than what researchers find in raw sewage The Marfella study in The New England Journal of Medicine: microplastics in arterial plaques and why it also lacked blank controls How microplastics could enter the body: skin absorption, ingestion, and inhalation Why PM2.5 monitoring already captures the most relevant airborne microplastic exposure What the WHO, FDA, and European Food Safety Authority have concluded about microplastic harm What better microplastics research would actually look like Why the real lesson is about how we evaluate headlines, not just microplastics Dr. Oliver Jones is Professor of Analytical Chemistry and Associate Dean of Biosciences and Food Technology at RMIT University in Melbourne. A Fellow of the Royal Society of Chemistry (FRSC) and the Royal Australian Chemical Institute (FRACI), he holds degrees from Imperial College London and Cambridge. He is one of only 118 scientists worldwide named to the IUPAC Periodic Table of Outstanding Younger Chemists. His research focuses on developing methods to measure environmental contaminants, including microplastics, and he was among the first scientists to publicly challenge the methodology of the viral "microplastics in the brain" study. Follow Dr. Jones: @dr_oli_jones RMIT faculty page: rmit.edu.au/oliver-jones Dr. Michelle Wong (Lab Muffin Beauty Science) first flagged the methodological concerns to us. Hosted by Drs. Ayesha & Dean Sherzai Subscribe to The Synapse (free weekly newsletter): https://thebraindocs.com/newsletter  Follow @TheBrainDocs on Instagram

For this episode, we're joined by Jesse Nippert, Professor in Biology at Kansas State University, and Chris Helzer, Director of Science and Stewardship for the Nature Conservancy in Nebraska. They were on the show to discuss their recent BioScience article "Rethinking grassland management in the Great Plains during the era of woody plant encroachment."

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.See omnystudio.com/listener for privacy information.

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Download the transcript here

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Listen to the podcast here

On this episode of The Hennessy Report, Dave Hennessy is joined by Robert Buckley, Chief People Architect at Enveda Biosciences, alongside colleague Jill Thompson, for a conversation on modern HR leadership, people strategy, and building high-performing cultures. Key topics include: • Principle-based leadership vs. policy-driven HR • Coaching-style management and developing stronger people leaders • Using data and analytics to improve HR decision-making • The impact of microlearning and continuous leadership development • Building a people-first culture in fast-growing organizations • Executive career decision-making with Howard Seidel in Coach's Corner A practical, forward-thinking discussion for HR leaders navigating leadership development, employee experience, and organizational growth.

This week on The Hamilton Review Podcast, we're pleased to welcome Dr. Stephanie Culler. Stephanie Culler, Ph.D., is the co-founder and CEO of Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines. In this episode, Dr. Culler shares about all about the company, including how a first-of-its-kind combination of probiotics and prebiotics replenishes key Bifidobacterium linked to healthier digestion, improved sleep and immune development for your baby. Parents, don't miss this informative conversation. Stephanie Culler, Ph.D., is the co-founder and CEO of Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines. Her microbiome interests span applications ranging from infant health to oncology and food as medicine. She has shared her work at TEDx San Diego, has been published in Science Magazine, and is a scientific pioneer in the field of synthetic biology. Stephanie holds a Ph.D. from the California Institute of Technology and has authored over twenty publications and patents on synthetic biology and microbial-based technologies.   How to contact Stephanie Culler:   Persephone Biosciences, Inc.   Persephone on Instagram   Persephone on LinkedIn   Persephone on TikTok     How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/    

Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well."   #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Download the transcript here

Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production. Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich's ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day." "So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich's ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs." "In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well."   #SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences solidbio.com Listen to the podcast here

What if the future of marketing is not just knowing what people will do, but understanding why they feel the way they do? In this episode, Joy Allen-Altimare unpacks predictive emotional modelling, and why the next leap in data driven marketing will come from combining behaviour, context and human emotion.

Can we control a virtual body as naturally as our own—using only brain activity? This question, inspired by the iconic series Sword Art Online, was set by Taiga Seri, a PhD researcher at Keio University. Answering this question led Taiga to the nomination for the International BCI Award, bringing all of us one step closer to a future once imagined in science fiction.

This CEO Is Creating A Vaccine To Cure Breast Cancer - Meet Dr. Amit Kumar, Chairman/CEO of Anixa Biosciences $ANIXGuestDr. Amit Kumar, Chairman and CEO of Anixa BiosciencesAnixa Biosciences, www.Anixa.com, NASDAQ:ANIXCompany InfoAnixa BiosciencesNASDAQ:ANIXhttps://www.Anixa.com/Amit's Bio:AMIT KUMAR, PH.D.Chairman & Chief Executive OfficerDr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market.He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies.He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.Company Bio:Anixa is a biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.Anixa's vaccine portfolio consists of technology focused on the immunization against specific “retired” proteins associated with breast cancer, specifically triple negative breast cancer (TNBC), and ovarian cancer. Further, Anixa is developing additional “retired tissue specific protein” vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. Retired proteins are proteins that are expressed at certain times in life and then are no longer expressed in healthy people.Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

For today's episode, we're joined by Luiza F. A. de Paula, Vanessa Handley, Raphael Ocelli, and Peggy Fielder, who are four of the authors of the recent BioScience article "Beyond Scents: Calling on the Fragrance Industry to Champion Plant Diversity." In it, they describe The Red List Project, which is a conservation-first initiative that pairs partners from the fragrance industry with local environmental groups and communities to achieve biodiversity objectives and safeguard biocultural heritage, while creating viable fragrance products.  Learn more about one of the initiatives discussed in the podcast, the Magnolia masphi fragrance, in this podcast episode from Beyond the Journey.

Governor Braun commits $1 billion to bioscience sector growth, aiming to create 100,000 jobs over 10 years. Indiana ranked worst of all states for foreclosure filing rates, with Indianapolis and Evansville among the top 5 of cities with the highest rates. The FSSA could end Medicaid drug reimbursement for qualified health centers state-wide. Host Jill Sheridan is joined by political strategist Elise Shrock, Republican Chris Mitchem, Samantha Horton of WFYI, and Niki Kelly of the Indiana Capital Chronicle to debate and discuss this week's top stories.

Governor Braun commits $1 billion to bioscience sector growth, aiming to create 100,000 jobs over 10 years. Indiana ranked worst of all states for foreclosure filing rates. The FSSA could end Medicaid drug reimbursement for qualified health centers.

Interview with Dr. Mark Williams, President & CSO, and  J. Roderick Matheson, Director & CEO of Marvel Bioscience Corp.Recording date: 16th March 2026Marvel Biosciences is advancing MB-204, a first-in-class treatment for social withdrawal conditions across autism spectrum disorder, depression, and Alzheimer's disease. The clinical-stage biotechnology company targets an underserved therapeutic area affecting millions globally, with autism prevalence reaching one in 36 children in the United States and depression impacting one in eight adults currently on antidepressants. The addressable market spans hundreds of billions of dollars in healthcare costs and lost productivity.The compound is based on a modified version of an approved Parkinson's medication, providing an established safety foundation for clinical development. Preclinical data demonstrates rapid symptom reversal within one hour of oral dosing in animal models. In head-to-head comparisons, MB-204 outperformed trofinetide, the only FDA-approved Rett syndrome treatment, across all measured behavioral endpoints. Critically, animals treated with MB-204 maintained improvements for two to three weeks after treatment cessation, suggesting semi-permanent neurological changes, while trofinetide benefits disappeared immediately upon stopping.Marvel's clinical strategy prioritizes orphan disease indications, specifically Rett syndrome and Fragile X syndrome, where Phase 3 success rates exceed 50% due to genetically homogeneous patient populations and validated regulatory pathways. The company has completed manufacturing of clinical-grade material and toxicology studies, positioning MB-204 for immediate Phase 1 entry in Australia within six to twelve months. The Australian regulatory environment offers efficient processes and a 43% research tax credit that significantly reduces development costs.Marvel holds composition of matter patents in China and Japan, with additional jurisdictions pending. The company has engaged in preliminary partnership discussions, aligning with neuroscience sector dynamics where approximately 70% of companies complete licensing or acquisition deals before Phase 2. Historical precedents show neuroscience acquisitions typically occur at valuations exceeding $80 million at this stage. Trading at $9 million CAD market capitalization, Marvel represents a significant discount to comparable Phase 1 neuroscience firms, with several peers valued between $100-400 million.Sign up for Crux Investor: https://cruxinvestor.com

Send a textIn this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Stephanie Culler, co-founder and CEO of Persephone Biosciences, to explore one of the most rapidly evolving frontiers in modern health science: the human microbiome. From early immune development to cancer therapy, the conversation reveals how the trillions of microbes living in our bodies may shape health in ways scientists are only beginning to understand.Dr. Culler's path into microbiome research began with a personal mission to understand disease after losing both of her grandmothers to cancer. Following her PhD at the California Institute of Technology, where she studied gene therapy approaches to cancer, she moved into industrial biotechnology and microbial engineering. That work eventually led her to co-found Persephone Biosciences, a company focused on translating microbiome science into real-world therapeutics and consumer health solutions.A major focus of the discussion centers on the infant microbiome and its role in shaping immune development. Dr. Culler explains how microbes transferred during birth and nourished through breast milk help “train” the immune system in the earliest stages of life. Yet modern research suggests that key beneficial bacteria—particularly Bifidobacterium infantis—have dramatically declined in Western infants. In large-scale studies conducted by Persephone, only a small percentage of U.S. infants carry adequate levels of this once-dominant microbe.The conversation also explores how microbiome balance may influence responses to cutting-edge cancer treatments like immunotherapy. Emerging research suggests that gut bacteria can significantly affect how patients respond to checkpoint inhibitors, opening the door to microbiome-based interventions that could enhance treatment outcomes.Listen to the full episode to hear Dr. Stephanie Culler explain how microbiome science is transforming our understanding of immunity, disease prevention, and the future of medicine.Learn more about Persephone BiosciencesDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

En este episodio hablamos con la Dra. Kelly Weinersmith, bióloga, parasitóloga y autora de ciencia popular. Kelly es investigadora asociada y profesora adjunta en el Departamento de BioSciences de Rice University, y su trabajo se centra en parásitos que manipulan el comportamiento de sus huéspedes, uno de los fenómenos más fascinantes de la biología. Además de su investigación científica, Kelly es conocida por acercar la ciencia al público a través de libros, charlas y podcasts. Es coautora de los bestsellers “Soonish” y “A City on Mars”, donde explora tecnologías emergentes y los retos reales de colonizar otros planetas. En la conversación hablamos sobre su investigación en parasitología, cómo los parásitos pueden controlar a otros organismos, el papel de la ciencia en el podcasting y la divulgación, y también nos adentramos en una de las grandes preguntas del futuro: si realmente podríamos vivir en Marte y qué problemas biológicos tendríamos que resolver para hacerlo posible.http://www.weinersmith.com/https://www.iheart.com/podcast/105-daniel-and-kellys-extraord-29862087/https://www.instagram.com/curiosidacientificapodcasthttps://jaboneradongato.com/Codigo; Curiosidad

Send a textIn this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa' clinical pipeline and strategic direction. He outlines the company's plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the Phase 1 study of Lira‑Cel, Anixa' CAR‑T therapy for ovarian cancer, observed in a terminally ill patient population. Dr. Kumar also details key protocol enhancements in the ongoing Phase 1 trial, to help steer the program toward potentially groundbreaking curative outcomes. Finally, supported by Anixa's capital‑efficient business model, Dr. Kumar notes that the expansion of clinical data in 2026 could drive meaningful opportunities for pharma partnerships and further validate the company's broader immunotherapy strategy.

Brian Stolz has cracked the code — literally and figuratively — on what it takes to build thriving teams in biotech. Episode 110 of The Hennessy Report by Keystone Partners features Brian Stolz, Chief People Officer at Element Biosciences, joined by Keystone Partners West Coast Market Leader Charlene Hutchins. Brian shares how growing up in Tokyo shaped his global perspective, his philosophy on building high-performing teams through diversity of thought, and how Element Bio's culture is rooted in respect, authenticity, and collaboration. He also dives into how AI is transforming HR and talent management, why the bio life sciences industry is poised for a major turnaround, and what he sees driving investment in the sector heading into 2026. Plus, Keystone's Vicky Rayel closes out the episode with practical career development advice in Coach's Corner.

Ashley Beckwith is the founder and CEO of Foray Bioscience, where she and her team leverage plant cell culture to createpredictable access to the plants and plant products the world needs, by growing them from the cell up. Ashley's path into the world of plants has been a curious one. She holds a Ph.D. in Mechanical Engineering from MIT and hasbeen innovating at the intersection of biology, materials, and manufacturing for over a decade. Her award-winning Ph.D. research led to the first demonstration of lab-grown “wood”, combining principles of tissue engineering and plant culture to grow structured plant materials in the lab. Now, Ashley leads Foray's team of plant biologists, process engineers, software developers, and machine learningexperts to make plant cell and tissue culture predictable and accessible for applications from micropropagation to fabricated seed production. 

January 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Sword Health acquires Kaia Health for $285M, expanding AI Care platform into Germany's 70M+ person reimbursement system Flo Health and Mayo Clinic study finds U.S. women lag behind UK, Canada, and Australia in recognizing perimenopause symptoms Life Biosciences receives FDA clearance for first human trial of partial cellular reprogramming, targeting glaucoma using gene therapy More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Tiffany Libby for a clear, science-forward conversation on supplements, cellular energy, and why NAD biology has become such a focal point in modern longevity discussions. As interest in “aging better” grows, this episode cuts through hype to explore what NAD optimization can—and cannot—realistically do for skin and whole-body health.Dr. Libby brings a rare perspective to the conversation. As a board-certified dermatologist and Director of Mohs Surgery at Brown University Health, her work spans both skin cancer care and cosmetic dermatology, treating patients across decades of life. That long view has shaped her understanding of longevity not as youth preservation, but as maintaining resilience, repair capacity, and function over time—especially in the face of inflammation, environmental stress, and chronic disease.Much of the discussion centers on why supplements, particularly NAD boosters, are having a cultural moment. Dr. Libby explains that this surge reflects a gap in the healthcare system itself—one that prioritizes treatment over prevention. While supplements can offer support, she emphasizes they are not shortcuts. Longevity still rests on fundamentals: sleep, nutrition, movement, stress regulation, and inflammation control.The episode offers a practical breakdown of NAD (nicotinamide adenine dinucleotide), explaining its role in mitochondrial energy production, DNA repair, and cellular defense. As NAD levels decline with age, skin becomes less efficient at repairing damage, producing collagen, and maintaining barrier integrity. Crucially, Dr. Libby explains why NAD itself can't be absorbed directly—and why precursors like nicotinamide riboside (NR) matter instead.Throughout the conversation, skepticism and safety remain central themes. In an underregulated supplement space, quality, dosing, and clinical validation matter. From a dermatologic standpoint, supporting mitochondrial health may help skin function closer to its biological potential—but only when paired with evidence-based care and realistic expectations.Listen to the full episode of Skin Anarchy to hear Dr. Tiffany Libby unpack the science of NAD, cellular energy, and why longevity begins with supporting biology—not chasing promises.SHOP TRU NIAGENDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

If you're a moth trying to stay uneaten, there are competing strategies. Some moths rely on camouflage, trying to blend in. Other moths take the opposite approach: They're bold and bright, with colors that say “don't eat me, I'm poison.” Biologist Iliana Medina joins Host Flora Lichtman to describe a study that placed some 15,000 origami moths in forests around the world to investigate which strategy might work best. Then, mammologist Anderson Feijó and evolutionary biologist Rafaela Missagia join Flora to dive into another evolutionary conundrum: why so many rodents have thumbnails. Guests: Dr. Iliana Medina Guzman is a Senior Lecturer in the School of BioSciences at the University of Melbourne in Australia.Dr. Anderson Feijó is a mammal curator at the Field Museum in Chicago. Dr. Rafaela Missagia is an assistant professor at the University of São Paulo in Brazil.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.